EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

被引：14

作者：

Michels, Sebastian ^{[1
]}

Gardizi, Masyar ^{[1
]}

Schmalz, Petra ^{[2
]}

Thurat, Meike ^{[1
]}

Pereira, Eva ^{[3
]}

Sebastian, Martin ^{[4
]}

Carcereny, Enric ^{[5
]}

Corral, Jesus ^{[6
]}

Paz-Ares, Luis ^{[6
]}

Felip, Enriqueta ^{[7
]}

Grohe, Christian ^{[8
]}

Rodriguez Abreu, Delvys ^{[9
]}

Insa Molla, Amelia ^{[10
]}

Bischoff, Helge ^{[11
]}

Reck, Martin ^{[12
]}

Karachaliou, Niki ^{[13
,14
]}

Scheel, Andreas ^{[15
]}

Brandes, Vanessa ^{[1
]}

Rieke, Fischer ^{[1
]}

Nogova, Lucia ^{[1
]}

Scheffler, Matthias ^{[1
]}

Franklin, Jeremy ^{[16
]}

Hellmich, Martin ^{[16
]}

Massuti, Bartomeu ^{[17
]}

Buettner, Reinhard ^{[15
]}

Rosell, Rafael ^{[18
]}

Wolf, Juergen ^{[1
]}

机构：

[1] Univ Hosp Cologne, Lung Canc Grp Cologne, Cologne, Germany

[2] Clin Trial Ctr Cologne, Cologne, Germany

[3] Spanish Lung Canc Grp, Barcelona, Spain

[4] Univ Klin Frankfurt Main, Frankfurt, Germany

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol, Badalona, Spain

[6] Hosp Univ Virgen Del Rocio, Seville, Spain

[7] Vall DHebron Univ Hosp, Barcelona, Spain

[8] Evangel Lungenklin, Berlin, Germany

[9] Univ Hosp Maternoinfantil Canarias, Las Palmas Gran Canaria, Spain

[10] Univ Hosp Clin Valencia, Med Oncol, Valencia, Spain

[11] Thoraxklin Heidelberg, Heidelberg, Germany

[12] Lungclin Grosshansdorf, Grosshansdorf, Germany

[13] Hosp Sagrat Cor, Barcelona, Spain

[14] Germans Trias & Pujol Hlth Sci Inst & Hosp, Barcelona, Spain

[15] Univ Hosp Cologne, Inst Pathol, Cologne, Germany

[16] Univ Hosp Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany

[17] Alicante Univ Hosp, Med Oncol, Alicante, Spain

[18] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

NSCLC; crizotinib; ros1;

D O I：

10.1016/j.jtho.2016.11.428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.05

引用

页码：S379 / S380

页数：2

共 50 条

[31] Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
Ryu, Woo Kyung
Cha, Hyungkeun
Park, Mi Hwa
Kim, Jung Soo
Choi, Jeong-Seok
Kim, Lucia
Lee, Kyung-Hee
Nam, Hae-Seong
FRONTIERS IN ONCOLOGY, 2022, 12
[32] Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR–ROS1 fusion
Hang Li
Yunjian Pan
Rui Wang
Yuan Li
Yihua Sun
Haiquan Chen
Journal of Cancer Research and Clinical Oncology, 2015, 141 : 185 - 187
[33] ALK and ROS1 Rearrangements Tested by Fluorescence In Situ Hybridization in Cytological Smears From Advanced Non-Small Cell Lung Cancer Patients
Bozzetti, Cecilia
Nizzoli, Rita
Tiseo, Marcello
Squadrilli, Anna
Lagrasta, Costanza
Buti, Sebastiano
Gasparro, Donatello
Zanoni, Daniele
Majori, Maria
De Filippo, Massimo
Mazzoni, Francesca
Maddau, Cristina
Naldi, Nadia
Sammarelli, Gabriella
Frati, Caterina
Pinto, Carmine
Ardizzoni, Andrea
DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 941 - 946
[34] Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
Yan, Ning
Huang, Si
Li, Lin
Guo, Qian
Geng, Di
Zhang, Hui
Guo, San
Li, Xing
FRONTIERS IN PHARMACOLOGY, 2022, 13
[35] Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
Song, Zhengbo
Yu, Xinmin
Zhang, Yiping
CANCER BIOLOGY & THERAPY, 2017, 18 (11) : 883 - 887
[36] Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
Lu, Shun
Pan, Hongming
Wu, Lin
Yao, Yu
He, Jianxing
Wang, Yan
Wang, Xiuwen
Fang, Yong
Zhou, Zhen
Wang, Xicheng
Cai, Xiuyu
Yu, Yan
Ma, Zhiyong
Min, Xuhong
Yang, Zhixiong
Cao, Lejie
Yang, Huaping
Shu, Yongqian
Zhuang, Wu
Cang, Shundong
Fang, Jian
Li, Kai
Yu, Zhuang
Cui, Jiuwei
Zhang, Yang
Li, Man
Wen, Xinxuan
Zhang, Jie
Li, Weidong
Shi, Jianhua
Xu, Xingxiang
Zhong, Diansheng
Wang, Tao
Zhu, Jiajia
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[37] A Phase II Study of Lorlatinib in Advanced ROS1+NSCLC Pre-Treated with Crizotinib and PlatinumBased Chemotherapy
Chen, H.
Wu, Y. -L.
Huang, Z.
Sun, L.
Li, X.
Chen, L.
Li, J.
Zhu, Z.
Zhuang, W.
Lu, K.
Zhang, Y.
Wang, K.
Chen, Y.
Huang, D.
Zhao, J.
He, Y.
Zhang, P.
Meng, X.
Du, Y.
Guo, Y.
Dong, X.
Liu, A.
Li, J.
Cang, S.
Wang, Q.
Fang, T.
Dai, H.
Yao, S.
Shi, Q.
Yang, J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S74 - S74
[38] Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study
Mourlanette, Jean
Rousseau-Bussac, Gaelle
Mallah, Siham
Guisier, Florian
Zalcman, Gerard
Veillon, Remi
Audigier-Valette, Clarisse
Roa, Magali
Nicolle, Isabelle
Doubre, Helene
Cloarec, Nicolas
Lamy, Regine
Morel, Hugues
Curcio, Hubert
Lagrange, Aurelie
Schott, Roland
Sabatini, Marielle
Toffart, Anne Claire
Pinsolle, Julian
Bennouna, Jaafar
Chouaid, Christos
Mazieres, Julien
TARGETED ONCOLOGY, 2025, 20 (02) : 311 - 317
[39] ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases
Song, Zhengbo
Zheng, Yuhui
Wang, Xuzhou
Su, Haiyan
Zhang, Yiping
Song, Yong
JOURNAL OF THORACIC DISEASE, 2017, 9 (10) : 3919 - +
[40] Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
Zhang, Na
Yang, Jin-Ji
Zhang, Xu-Chao
Xie, Zhi
Wang, Bin-Chao
Tu, Hai-Yan
Jiang, Ben-Yuan
Wu, Yi-Long
ONCOLOGY LETTERS, 2014, 8 (06) : 2624 - 2626

← 1 2 3 4 5 →